Discovery and development of direct Xa inhibitors Xa was identified as a promising target for the development of new anticoagulants in the early 1980s. In 1987 the first factor Xa inhibitor, the naturally occurring compound antistasin, was isolated from the salivary glands of the Mexican leech "Haementeria officinalis". Antistasin is a polypeptide and a potent Xa inhibitor. In 1990 another naturally occurring Xa inhibitor was isolated, tick anticoagulant peptide (TAP) from extracts of the tick "Ornithodoros moubata". TAP and antistasin were used to estimate factor Xa as a drug target. Blood coagulation is a complex process by which the blood forms clots. It is an essential part
Custom peptide synthesis peptide or protein using a rational design approach, small and large amounts of peptides are needed, Some in the milligram scale. Once a desired activity or potency is identified, larger scale synthesis is need. For this, gram to multi-gram scale may be needed in order to initiate small animal studies. Often, after successful validation, an even larger scale of synthesis may be desired. These can range in scale from hundreds of grams to multi-kilo amounts. Custom peptide synthesis Custom peptide synthesis is the commercial production of peptides for use in biochemistry, biology, biotechnology, pharmacology and molecular medicine. Custom peptide synthesis